Idppid

Boehringer Ingelheim's IDPPID initiative is dedicated to the diagnosis and management of Pituitary Pars Intermedia Dysfunction (PPID), one of the most prevalent equine endocrine disorders. Affecting about 21% of horses over the age of 15, PPID can present a range of clinical signs such as delayed shedding, loss of muscle mass, and lethargy. Boehringer Ingelheim offers a comprehensive testing program to help equine owners and veterinarians identify and confirm PPID in affected horses.

The program guides users through a straightforward enrollment process, making it easy to submit plasma samples for testing. Results are typically available within 3 to 5 working days from the Cornell University Animal Health Diagnostic Center. With extensive resources covering diagnosis, management options, and clinical signs of PPID, Boehringer Ingelheim strives to support horse owners in early detection and care, ensuring their horses lead healthier lives. For assistance, the customer care team is available during business hours.